4:00 AM
 | 
Apr 18, 2019
 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

How Arrakis is plotting a path forward with its RNA-targeting small molecules

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become an integrated, publicly traded biopharma.

Arrakis Therapeutics Inc. has begun its first four programs developing RNA-targeting small molecules -- "rSMs" -- including three oncology programs and one cardiovascular project. But the company's broadly applicable science could eventually yield candidates in multiple therapeutic areas, opening up potential partnerships, Chairman and CEO Michael Gilman told BioCentury.

For the new round, Arrakis sought "sophisticated company builders who were comfortable following companies into the public markets," Gilman said. "We built this syndicate with an eye on the long arc of the company."

venBio and Nextech Invest led the round, announced Thursday. The group...

Read the full 648 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >